These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 30904881)

  • 1. Correction:
    BMJ Open; 2019 Mar; 9(3):e019649corr1. PubMed ID: 30904881
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomised controlled trial of a facilitated home-based rehabilitation intervention in patients with heart failure with preserved ejection fraction and their caregivers: the REACH-HFpEF Pilot Study.
    Lang CC; Smith K; Wingham J; Eyre V; Greaves CJ; Warren FC; Green C; Jolly K; Davis RC; Doherty PJ; Miles J; Britten N; Abraham C; Van Lingen R; Singh SJ; Paul K; Hillsdon M; Sadler S; Hayward C; Dalal HM; Taylor RS;
    BMJ Open; 2018 Apr; 8(4):e019649. PubMed ID: 29632081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Process evaluation of a randomised pilot trial of home-based rehabilitation compared to usual care in patients with heart failure with preserved ejection fraction and their caregiver's.
    Smith K; Lang C; Wingham J; Frost J; Greaves C; Abraham C; Warren FC; Coyle J; Jolly K; Miles J; Paul K; Doherty PJ; Davies R; Dalal H; Taylor RS;
    Pilot Feasibility Stud; 2021 Jan; 7(1):11. PubMed ID: 33407893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial.
    Maisel AS; Shah KS; Barnard D; Jaski B; Frivold G; Marais J; Azer M; Miyamoto MI; Lombardo D; Kelsay D; Iqbal N; Taub PR; Kupfer K; Lee E; Clopton P; Zile M; Greenberg B
    J Card Fail; 2016 Apr; 22(4):283-93. PubMed ID: 26433086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart failure with preserved vs reduced ejection fraction following cardiac rehabilitation: impact of endothelial function.
    Tanaka S; Sanuki Y; Ozumi K; Harada T; Tasaki H
    Heart Vessels; 2018 Aug; 33(8):886-892. PubMed ID: 29392470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a 6-month pedometer-based walking intervention on functional capacity in patients with chronic heart failure with reduced (HFrEF) and with preserved (HFpEF) ejection fraction: study protocol for two multicenter randomized controlled trials.
    Vetrovsky T; Siranec M; Parenica J; Griva M; Stastny J; Precek J; Pelouch R; Bunc V; Linhart A; Belohlavek J
    J Transl Med; 2017 Jul; 15(1):153. PubMed ID: 28673328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidisciplinary rehabilitation program in recently hospitalized patients with heart failure and preserved ejection fraction: rationale and design of a randomized controlled trial.
    Koifman E; Grossman E; Elis A; Dicker D; Koifman B; Mosseri M; Kuperstein R; Goldenberg I; Kamerman T; Levine-Tiefenbrun N; Klempfner R
    Am Heart J; 2014 Dec; 168(6):830-7.e1. PubMed ID: 25458645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart Failure with Preserved Ejection Fraction Trials Have Heterogeneous Control Groups: a Comparison of Kaplan-Meier Curves.
    Luo H; Zhang C; Wang J; Zhu J; Jia X
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):577-580. PubMed ID: 30187346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Eligibility Criteria in Phase III Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection Fraction: The Critical Play-Off Between a "Pure" Patient Phenotype and the Generalizability of Trial Findings.
    Patel HC; Hayward C; Dungu JN; Papadopoulou S; Saidmeerasah A; Ray R; Di Mario C; Shanmugam N; Cowie MR; Anderson LJ
    J Card Fail; 2017 Jul; 23(7):517-524. PubMed ID: 28434933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    Paulus WJ; Tschöpe C
    J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
    Trippel TD; Van Linthout S; Westermann D; Lindhorst R; Sandek A; Ernst S; Bobenko A; Kasner M; Spillmann F; González A; López B; Ravassa S; Pieske B; Paulus WJ; Díez J; Edelmann F; Tschöpe C
    Eur J Heart Fail; 2018 Mar; 20(3):460-470. PubMed ID: 28891228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.
    Lund LH; Benson L; Dahlström U; Edner M
    JAMA; 2012 Nov; 308(20):2108-17. PubMed ID: 23188027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Heart Failure with Preserved Ejection Fraction.
    Ilieșiu AM; Hodorogea AS
    Adv Exp Med Biol; 2018; 1067():67-87. PubMed ID: 29498023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac diastolic and autonomic dysfunction are aggravated by central chemoreflex activation in heart failure with preserved ejection fraction rats.
    Toledo C; Andrade DC; Lucero C; Arce-Alvarez A; Díaz HS; Aliaga V; Schultz HD; Marcus NJ; Manríquez M; Faúndez M; Del Rio R
    J Physiol; 2017 Apr; 595(8):2479-2495. PubMed ID: 28181258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ejection fraction in patients with heart failure and preserved ejection fraction is greater than in healthy controls: a meta-analysis.
    Dori G; Rajab I; David K; Naama S; Moshe V
    Eur J Intern Med; 2014 Nov; 25(9):831-6. PubMed ID: 25303783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy of heart failure with preserved ejection fraction.
    Basaraba JE; Barry AR
    Pharmacotherapy; 2015 Apr; 35(4):351-60. PubMed ID: 25884524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study.
    Kontogeorgos S; Thunström E; Johansson MC; Fu M
    Int J Cardiol; 2017 Apr; 232():86-92. PubMed ID: 28100428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial.
    Zile MR; Gaasch WH; Anand IS; Haass M; Little WC; Miller AB; Lopez-Sendon J; Teerlink JR; White M; McMurray JJ; Komajda M; McKelvie R; Ptaszynska A; Hetzel SJ; Massie BM; Carson PE;
    Circulation; 2010 Mar; 121(12):1393-405. PubMed ID: 20231531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exercise training improves cardiac autonomic control, cardiac function, and arrhythmogenesis in rats with preserved-ejection fraction heart failure.
    Andrade DC; Arce-Alvarez A; Toledo C; Díaz HS; Lucero C; Schultz HD; Marcus NJ; Del Rio R
    J Appl Physiol (1985); 2017 Sep; 123(3):567-577. PubMed ID: 28620053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose.
    Pierce JD; Mahoney DE; Hiebert JB; Thimmesch AR; Diaz FJ; Smith C; Shen Q; Mudaranthakam DP; Clancy RL
    BMC Cardiovasc Disord; 2018 Apr; 18(1):57. PubMed ID: 29606104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.